Report cover image

Plunkett's Biotech, Pharmaceuticals & Genetics Industry Almanac 2024: Biotech, Pharmaceuticals & Genetics Industry Market Research, Statistics, Trends and Leading Companies

Publisher Plunkett Research, Ltd.
Published Aug 22, 2023
Length 491 Pages
SKU # PLK18146293

Description

PLUNKETT'S BIOTECH, PHARMACEUTICALS & GENETICS INDUSTRY ALMANAC 2024


Key Findings:

A complete market research report, including forecasts and market estimates, technologies analysis and developments at innovative firms within the Biotech, Pharmaceuticals & Genetics Industry. Gain vital insights that can help shape strategy for business development, product development and investments.

Key Features:
  • Business trends analysis
  • In-depth industry overview
  • Technology trends analysis
  • Forecasts
  • Spending, investment, and consumption discussions
  • In-depth industry statistics and metrics
  • Industry employment numbers
Additional Key Features Include:

Industry Glossary

Industry Contacts list, including Professional Societies and Industry Associations

Profiles of industry-leading companies
  • U.S. and Global Firms
  • Publicly held, Private and Subsidiaries
  • Executive Contacts
  • Revenues
  • For Public Companies: Detailed Financial Summaries
Pages: 496
Statistical Tables Provided: 8
Companies Profiled: 350
Geographic Focus: Global

Key Questions Answered Include:
  • How is the industry evolving?
  • How is the industry being shaped by new technologies?
  • How is demand growing in emerging markets and mature economies?
  • What is the size of the market now and in the future?
  • What are the financial results of the leading companies?
  • What are the names and titles of top executives?
  • What are the top companies and what are their revenues?
This feature-rich report covers competitive intelligence, market research and business analysis—everything you need to know about the Biotech, Pharmaceuticals & Genetics Industry.

Plunkett Research Provides Unique Analysis of the Following Major Trends Affecting the Biotech, Pharmaceuticals & Genetics Industry

1. The State of the Biotechnology Industry Today
2. The Coronavirus’ Effect on the Biotech, Pharmaceuticals & Genetics Industry
3. A Short History of Biotechnology
4. Fast Track Drugs Come to Market in the U.S. with FDA Cooperation
5. Ethanol Production Soared, But U.S. Federal Subsidy Expired
6. Cellulosic Ethanol Makes Slow Commercial Progress
7. Major Drug Companies Acquire or Partner With Smaller Biotech Firms
8. Pharmaceutical R&D Improves with Artificial Intelligence (AI)
9. From Korea to India to Singapore to China, Nations Compete Fiercely in Biotech Development
10. Patients’ Genetic Profiles Plummet in Price as DNA Sequencing Technologies Advance
11. Gene Therapies Target Defective Genes/CRISPR Advances DNA Editing
12. Vaccines & Viruses as Therapies/mRNA Shows Great Promise
13. Massive R&D Investment Required for Development and Approval of New Drugs/Drug Prices Soar
14. Generic Drugs Have Biggest Market Share by Unit Volume, but not by Total Revenues
15. America Pays Higher Prices for Drugs Than Other Nations/U.S. Government Launches Drug Price Negotiation and Control Powers for Medicare
16. Biotech and Orphan Drugs Create New Revenues for Drug Firms
17. Revolutionary New Drugs (Ozempic, Wegovy) Treat Obesity, Diabetes and Addiction
18. Biosimilars (Generic Biotech Drugs) Receive FDA Guidelines for Accelerated Approval/Competition Will Be Fierce
19. Market for CBD
20. Stem Cells and 3-D Printing—A New Era of Tissue Replacement Takes Shape
21. Genetically Modified (GM) Seeds and Crops Planted in Dozens of Nations/Agribio R&D Investment Is High
22. Genetically Modified (GM) Foods Prompt Controversy, Labeling and Legislation
23. Plant-Based Meat Substitutes Developed
24. Selective Plant Breeding, Mutagenesis and Gene-Editing, Including CRISPR, as Alternatives to GM Seeds
25. Immunotherapy, ADCs and CAR-T Create Exciting New Approach to Fighting Cancers
26. Technology Discussion—Genes and DNA
27. Technology Discussion—Proteins and Proteomics
28. Technology Discussion—DNA Chips
29. Technology Discussion—SNPs (“Snips”)
30. Technology Discussion—Synthetic Biology
31. Technology Discussion—Recombinant DNA
32. Technology Discussion—Polymerase Chain Reaction (PCR)

Plunkett Research Provides In-Depth Tables for the Following Biotech, Pharmaceuticals & Genetics Industry Statistics

1. Biotech Industry Statistics and Market Size Overview
2. The U.S. Drug Discovery & Approval Process
3. U.S. FDA New Drug (NDA) and Biologic (BLA) Approvals, 2022
4. Employment in Life & Physical Science Occupations by Business Type, U.S.: May 2022
5. Federal R&D & R&D Plant Funding for Basic Research, U.S.: Fiscal Years 2022-2024
6. U.S. Exports & Imports of Pharmaceutical Products: 2017-2022
7. Prescription Drug Expenditures, U.S.: Selected Years, 2015-2031
8. NSF Budget by Appropriation (Dollars in Millions), Fiscal Years 2022-2024

Table of Contents

491 Pages
Introduction
How to Use This Book
Chapter 1: Major Trends Affecting the Biotech, Pharmaceuticals & Genetics Industry
1) The State of the Biotechnology Industry Today
2) The Coronavirus’ Effect on the Biotech, Pharmaceuticals & Genetics Industry
3) A Short History of Biotechnology
4) Fast Track Drugs Come to Market in the U.S. with FDA Cooperation
5) Ethanol Production Soared, But U.S. Federal Subsidy Expired
6) Cellulosic Ethanol Makes Slow Commercial Progress
7) Major Drug Companies Acquire or Partner With Smaller Biotech Firms
8) Pharmaceutical R&D Improves with Artificial Intelligence (AI)
9) From Korea to India to Singapore to China, Nations Compete Fiercely in Biotech Development
10) Patients’ Genetic Profiles Plummet in Price as DNA Sequencing Technologies Advance
11) Gene Therapies Target Defective Genes/CRISPR Advances DNA Editing
12) Vaccines & Viruses as Therapies/mRNA Shows Great Promise
13) Massive R&D Investment Required for Development and Approval of New Drugs/Drug Prices Soar
14) Generic Drugs Have Biggest Market Share by Unit Volume, but not by Total Revenues
15) America Pays Higher Prices for Drugs Than Other Nations/U.S. Government Launches Drug Price Negotiation and Control Powers for Medicare
16) Biotech and Orphan Drugs Create New Revenues for Drug Firms
17) Revolutionary New Drugs (Ozempic, Wegovy) Treat Obesity, Diabetes and Addiction
18) Biosimilars (Generic Biotech Drugs) Receive FDA Guidelines for Accelerated Approval/Competition Will Be Fierce
19) Market for CBD
20) Stem Cells and 3-D Printing—A New Era of Tissue Replacement Takes Shape
21) Genetically Modified (GM) Seeds and Crops Planted in Dozens of Nations/Agribio R&D Investment Is High
22) Genetically Modified (GM) Foods Prompt Controversy, Labeling and Legislation
23) Plant-Based Meat Substitutes Developed
24) Selective Plant Breeding, Mutagenesis and Gene-Editing, Including CRISPR, as Alternatives to GM Seeds
25) Immunotherapy, ADCs and CAR-T Create Exciting New Approach to Fighting Cancers
26) Technology Discussion—Genes and DNA
27) Technology Discussion—Proteins and Proteomics
28) Technology Discussion—DNA Chips
29) Technology Discussion—SNPs (“Snips”)
30) Technology Discussion—Synthetic Biology
31) Technology Discussion—Recombinant DNA
32) Technology Discussion—Polymerase Chain Reaction (PCR)
Chapter 2: Biotech, Pharmaceuticals & Genetics Industry Statistics
Biotech Industry Statistics and Market Size Overview
The U.S. Drug Discovery & Approval Process
U.S. FDA New Drug (NDA) and Biologic (BLA) Approvals, 2022
Employment in Life & Physical Science Occupations by Business Type, U.S.: May 2022
Federal R&D & R&D Plant Funding for Basic Research, U.S.: Fiscal Years 2022-2024
U.S. Exports & Imports of Pharmaceutical Products: 2017-2022
Prescription Drug Expenditures, U.S.: Selected Years, 2015-2031
NSF Budget by Appropriation (Dollars in Millions), Fiscal Years 2022-2024
Chapter 3: Important Biotech, Pharmaceuticals & Genetics Industry Contacts
(Addresses, Phone Numbers and Internet Sites)
Chapter 4: THE BIOTECH 350:
Who They Are and How They Were Chosen
Index of Companies Within Industry Groups
Alphabetical Index
Index of U.S. Headquarters Location by State
Index of Non-U.S. Headquarters Location by Country
Individual Profiles on Each of THE BIOTECH 350
Additional Indexes
Index of Hot Spots for Advancement for Women/Minorities
Index by Subsidiaries, Brand Names and Selected Affiliations
A Short Biotech, Pharmaceuticals & Genetics Industry Glossary

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us